ArticleCanadian respiratory journal2026
Synergistic Effects of Erythromycin and Budesonide on the Mitigation of Tracheal Stenosis Associated With Macrophage Phenotype Alteration and HDAC2 Upregulation.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Effects of Erythromycin and Budesonide on the Mitigation of Tracheal Stenosis Associated With Macrophage Phenotype Alteration and HDAC2 Upregulation.Canadian respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveWe investigated the therapeutic effects of combined erythromycin and budesonide treatment on tracheal stenosis (TS) and the associated changes in macrophage-related markers and HDAC2 expression.
methodsA rabbit model of TS was established by mechanical scraping of the tracheal inner wall, and the animals were then treated with erythromycin, budesonide, or their combination. Treatment effects were evaluated through histological analysis. We quantified the mRNA expression of M1 and M2 macrophage markers using quantitative PCR and assessed the protein expression of histone deacetylase 2 (HDAC2) by western blotting. RAW264.7 cells were stimulated with lipopolysaccharide or interleukin-4, and macrophage phenotypic changes after erythromycin and budesonide treatment were assessed by flow cytometry. M1/M2 macrophages were co-cultured with fibroblasts, and alpha smooth muscle actin (α-SMA) expression was detected by immunofluorescence.
resultsThe rabbit TS model exhibited TS characterized by significant thickening of the tracheal mucosa and submucosa. These histological changes were ameliorated in the treatment groups, with the greatest improvement observed in the combination therapy group. The mRNA expression levels of iNOS, CD206, CD163, and Arg1, as well as the protein expression of HDAC2, were elevated in treated groups. In vitro, erythromycin combined with budesonide altered macrophage phenotypic distribution, with the M2/M1 ratio shifting toward 1.0. Additionally, fibroblast α-SMA expression varied according to macrophage phenotype in the co-culture system.
conclusionErythromycin combined with budesonide effectively ameliorated injury-induced TS and was associated with changes in macrophage-related markers and increased HDAC2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.